Sen. Kay Bailey Hutchison (R-Tex) is supporting a bill that would authorize the National Cancer Institute (NCI) to increase research on blood cancers, particularly leukemia, lymphoma, and multiple myeloma. The Senate Health, Education, Labor,
Sen. Kay Bailey Hutchison (R-Tex) is supporting a bill thatwould authorize the National Cancer Institute (NCI) to increase research on bloodcancers, particularly leukemia, lymphoma, and multiple myeloma. The SenateHealth, Education, Labor, and Pensions Committee approved the bill (S. 1094/H.R.2629) after making some changes on November 1.
At press time, it seems likelythat Congress will pass the bill before its 2001 session ends. One change theSenate committee made was removing its specific $250 million a year researchspending target. The bill now essentially encourages the NCI to spend more.However, figures provided by the NCI show it spent $238.8 million on those threecancers in fiscal 2000, the latest year for which figures are available.
Senatestaffers believe the figure is considerably less because the NCI sometimes"double counts" research projects, ie, puts them into more than onespending category. Blood cancers account for 11% of all cancer deaths, or 60,300persons annually. An estimated 109,500 people in the United States will bediagnosed with leukemia, lymphoma, and multiple myeloma in 2001.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.